Fluidigm Corp. filed a patent infringement suit against privately held IonPath Inc. in a U.S. district court related to its proprietary imaging technology.
In the lawsuit, the mass cytometry and microfluidics technologies company alleged that IONpath's multiplexed ion beam imaging, or MIBI, technology infringes U.S. patents covering Fluidigm's mass cytometry, or CyTOF, technology.
The South San Francisco, Calif.-based company is seeking damages and injunctive relief requiring IONpath to stop selling its MIBI technology.
"Fluidigm has made substantial investments in the research and development of its CyTOF technology. This lawsuit is aimed at protecting those investments," Fluidigm CEO Chris Linthwaite said in a press release.
